EUVIMEDEUVIMED entdecken
Crossref

Carbon-Ion Radiotherapy for Prostate Cancer in Hemodialysis Patients

Hikaru Imafuku, Kotaro Terashima, Kaori Fukunishi, Hiroaki Suefuji, Akira Matsunobu, Shingo Toyama, Wakana Ota, Yoshiyuki Shioyama

Anticancer Research · 2025

DOI: 10.21873/anticanres.17794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Hikaru Imafuku und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ion Beam Therapy Center, SAGA-HIMAT Foundation, Saga, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Renal Dialysis, Heavy Ion Radiotherapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Although the safety and efficacy of carbon ion radiation therapy (CIRT) are well established, its toxicity in the treatment of prostate cancer in patients undergoing hemodialysis has not been well determined. To evaluate this toxicity/safety, we retrospectively analyzed cases of patients with prostate cancer who had undergone CIRT. PATIENTS AND METHODS: The cases of 13 hemodialysis patients with localized or locally invasive prostate cancer who underwent CIRT at the Japanese Ion Beam Therapy Center, SAGA HIMAT Foundation between November 2013 and May 2023 were investigated. CIRT was delivered using either passive scattering or scanning techniques, with a total dose of 51.6 Gy (RBE) delivered in 12 fractions for all cases. Toxicity was assessed and analyzed based primarily on CTCAE version 5.0. RESULTS: In the acute phase, Grade 1 genitourinary (GU) toxicity was observed in three patients, and Grade 2 GU toxicity was observed in two patients. In the late phase, Grade 1 gastrointestinal toxicity was observed in one patient. No Grade 3 or higher toxicities were observed. Nine patients achieved recurrence-free survival. One patient experienced clinical recurrence. CONCLUSION: CIRT for prostate cancer can be safely administered even in hemodialysis patients, and its toxicities were within acceptable limits. Our findings suggest that CIRT has potential as a treatment option for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRenal DialysisHeavy Ion RadiotherapyHumansMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Carbon-ion radiotherapygastrointestinal toxicitygenitourinary toxicityhemodialysisprostate cancerradiation toxicity

Autor:innen und Institutionen

  • Ion Beam Therapy Center, SAGA-HIMAT Foundation, Saga, Japan.
  • Department of Radiology, Kyushu University Hospital, Fukuoka, Japan.
  • Ion Beam Therapy Center, SAGA-HIMAT Foundation, Saga, Japan; terashima-kotaro@saga-himat.jp.

Zitieren

APA

Imafuku, H., Terashima, K., Fukunishi, K., Suefuji, H., Matsunobu, A., Toyama, S., Ota, W., & Shioyama, Y. (2025). Carbon-Ion Radiotherapy for Prostate Cancer in Hemodialysis Patients. Anticancer Research. https://doi.org/10.21873/anticanres.17794

Vancouver

Imafuku H, Terashima K, Fukunishi K, Suefuji H, Matsunobu A, Toyama S, et al. Carbon-Ion Radiotherapy for Prostate Cancer in Hemodialysis Patients. Anticancer Research. 2025. doi:10.21873/anticanres.17794

BibTeX
@article{Imafuku2025,
  author = {Imafuku, Hikaru and Terashima, Kotaro and Fukunishi, Kaori and Suefuji, Hiroaki and Matsunobu, Akira and Toyama, Shingo and Ota, Wakana and Shioyama, Yoshiyuki},
  title = {Carbon-Ion Radiotherapy for Prostate Cancer in Hemodialysis Patients},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17794}
}
Kostenlos starten →